Aiming to become an agile specialty pharma trusted around the world

Since the start of the new millennium, Taiho Pharmaceutical has been pursuing global R&D while building its own sales structure in the U.S. and expanding its sales network in other countries. In recent years, the company has established two corporate venture capital firms to expand its development pipeline and promote the creation and utilization of innovation. Going forward, Taiho Pharmaceutical will continue to make every effort to increase its global reach, seeking to bring smiles to the faces of people around the world.

  • Global Specialty Pharma

Message from EUROPE

Properly delivering Taiho Pharmaceutical’s new drugs to patients from our new European base

Atsushi Azuma, Ph.D.

Taiho Oncology Europe was established in Zug, Switzerland in January 2021 to serve as the marketing company for the Taiho Group in Europe. By collaborating with other Otsuka group companies, we are currently building our own sales/marketing organization for the launch of the new oral anti-cancer agent futibatinib (development code: TAS-120), an FGFR inhibitor currently under development. Going forward, we hope to contribute to health and smiles for patients in Europe by promoting the proper use of our drugs and further expanding our lineup
of anticancer drugs while strengthening our organization.

Message from ASIA

Aiming to deliver innovative new drugs to as many people in Asia as possible

Yoshimasa Nishimura
Managing Director

Taiho Pharmaceutical of Beijing and Taiho Pharma Asia Pacific share the slogan, “By Local. For Local.” Our primary mission is to provide the innovative new drugs and unique consumer healthcare products developed by Taiho Pharmaceutical to medical professionals, to patients, and to all the people of Asian countries and regions, through the caring hands of our local employees. Our entire team is united to give our best effort every day to bring smiles to the faces of as many locals as possible.

Message from

Expanding our sales network from a global perspective and bringing Taiho harmaceutical’s philosophy to the world

Timothy Whitten
President & CEO

Taiho Oncology has embraced the Taiho Pharmaceutical corporate philosophy and it guides us in every important decision we make. It helps us understand what we should do as we strive to improve human health and contribute to a society enriched by smiles. The corporate philosophy tells us we should expand commercially into other geographic markets, we should embrace globalization, and we should invest in our pipeline and marketed products
globally. By doing that, it will allow more patients to benefit from our products, provide more financial resources to invest in our pipeline and marketed products development, and help the Taiho name become more well-known globally.